Inspire Medical Systems (NYSE:INSP) Given New $77.00 Price Target at Robert W. Baird

Inspire Medical Systems (NYSE:INSP) had its price target lifted by equities research analysts at Robert W. Baird from $73.00 to $77.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird‘s price objective suggests a potential upside of 14.04% from the stock’s previous close.

Several other analysts have also recently commented on INSP. Truist Financial lifted their price objective on shares of Inspire Medical Systems from $62.00 to $78.00 and gave the company a “hold” rating in a research note on Wednesday, October 14th. Stifel Nicolaus lifted their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the company a “buy” rating in a report on Friday, September 11th. Royal Bank Of Canada lifted their price target on Inspire Medical Systems from $60.00 to $75.00 and gave the company a “sector perform” rating in a research note on Thursday, October 1st. Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective on the stock in a report on Tuesday, August 4th. Finally, Evercore set a $54.00 price objective on Inspire Medical Systems in a research report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $71.24.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $67.52 on Tuesday. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03. The firm has a market capitalization of $1.95 billion, a PE ratio of 14.61, a P/E/G ratio of 5.37 and a beta of 0.73. The stock’s 50-day simple moving average is $68.69 and its 200-day simple moving average is $58.82.

Inspire Medical Systems (NYSE:INSP) last released its earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $206.69 million during the quarter, compared to the consensus estimate of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The company’s revenue was down 7.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 earnings per share. Sell-side analysts forecast that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the sale, the insider directly owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Inspire Medical Systems

A number of institutional investors have recently bought and sold shares of INSP. WINTON GROUP Ltd grew its stake in shares of Inspire Medical Systems by 790.8% in the 2nd quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock valued at $1,669,000 after buying an additional 33,212 shares during the period. Legal & General Group Plc purchased a new stake in shares of Inspire Medical Systems during the 2nd quarter valued at approximately $2,732,000. Alberta Investment Management Corp purchased a new stake in shares of Inspire Medical Systems during the 2nd quarter valued at approximately $5,483,000. Empowered Funds LLC acquired a new position in Inspire Medical Systems in the second quarter valued at approximately $2,260,000. Finally, GSA Capital Partners LLP purchased a new position in Inspire Medical Systems in the second quarter worth approximately $820,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

More Inspire Medical Systems News

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
• Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
• Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
• Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.